Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ZSP1601

Phase 2Small molecule

GGuangdong Raynovent Biotech Co., Ltd

ZSP1601 is one of 79 small molecule programs targeting Hepatitis. It is currently in Phase 2.

2

Indications

3

Total Trials

1

Active Trials

78

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

Actos

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Amoxil

GGlobal Antibiotics Research and Development Partnership

Hepatitis B Vaccine

Cervarix

Prevnar

Coenzyme Q10

MMclean Hospital

PI-88

CCellxpert Biotechnology Corp.

Recombinant Hepatitis B Vaccine

Varivax

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hepatitis

NCT05692492

Clinical

Trials by Indication[1]

Adult1 trial

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Completed·GGuangdong Zhongsheng Pharmaceutical Co., Ltd.·Phase 1·NCT03392779·94 enrolled

Non-Alcoholic Steatohepatitis1 trial

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1/2·NCT04140123·37 enrolled

Hepatitis1 trial

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 2·NCT05692492·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ZSP1601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZSP1601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZSP1601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Raynovent Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangdong Raynovent Biotech Co., Ltd

Related News